DRAIGON
Financiado
Diagnosing Infections with Multi-Drug Resistant Microorganisms using AI-powered...
Diagnosing Infections with Multi-Drug Resistant Microorganisms using AI-powered Genomic Antibiotic Susceptibility Prediction from Long-Read Sequencing Data
The silent pandemic of antimicrobial resistance (AMR) is a growing global health crisis with a projected annual mortality rate of 10 million by 2050. Addressing this crisis critically depends on fast, accessible and precise diagno...
The silent pandemic of antimicrobial resistance (AMR) is a growing global health crisis with a projected annual mortality rate of 10 million by 2050. Addressing this crisis critically depends on fast, accessible and precise diagnostics to improve detection and prevention of infection and guide antibiotic therapy. Current diagnostics often have insufficient turnaround time or data for timely detection and prevention of outbreaks or precision antibiotic therapy guidance, and accessibility is often limited due to the required infrastructure and expert personnel. To overcome these shortcomings, and address AMR, we are developing a diagnostic based on accelerated whole genome sequencing linked with AI-assisted data analysis. This project termed DRAIGON includes a consortium of internationally recognized experts in sequencing platform and assay development, bioinformatics and machine learning, clinical microbiology, infection prevention and control, antibiotic therapy and stewardship, and health economics to jointly develop our in vitro diagnostic solution to target virtually any pathogen-antibiotic combination. We propose to validate and demonstrate the clinical utility of DRAIGON focusing on bloodstream and prosthetic joint infections at five independent sites, including one located in a medium income country representative of areas with a high AMR burden and reduced access to laboratory infrastructure. The diagnostic will be easy to implement and functions as an early detection system to prevent the cross-border spread of pathogens. In rapidly and accurately providing pathogen ID and type, a comprehensive antibiogram, and outbreak cluster information directly from genome data and in a single assay, this innovative high-resolution diagnostic aims to reinforce the global fight against AMR infections and enable the antibiotic stewardship goals of right antibiotic, at the right dose, for the right patient, and at the right time.
ver más
Duración del proyecto: 48 meses
Fecha Inicio: 2023-12-13
Fecha Fin: 2027-12-31
Fecha Fin: 2027-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-13
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
7M€
Líder del proyecto
EUROPEAN VACCINE INITIATIVE E.V
No se ha especificado una descripción o un objeto social para esta compañía.
406.90K€ |
Participante
1.11M€ |
Participante